Drug:
Reaction: DISEASE PROGRESSION
20260101 - 20261231
No. 201 - 300
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 201 | 26901897 |
8 | 1 | |
Disease progression, |
||||
FAM-TRASTUZUMAB DERUXTECAN-NXKI, |
||||
| 202 | 26901899 |
61 | ||
Disease progression, Stomatitis, |
||||
DATOPOTAMAB DERUXTECAN, |
||||
| 203 | 26901900 |
51 | ||
Disease progression, |
||||
FAM-TRASTUZUMAB DERUXTECAN-NXKI, |
||||
| 204 | 26901901 |
2 | ||
Disease progression, |
||||
DATOPOTAMAB DERUXTECAN, |
||||
| 205 | 26901903 |
81 | 1 | |
Acute kidney injury, Abdominal pain upper, Constipation, Diarrhoea, Disease progression, Fatigue, Hypokalaemia, Nausea, Vomiting, |
||||
TRASTUZUMAB, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, |
||||
| 206 | 26901904 |
74 | 2 | |
Disease progression, Parotid gland enlargement, Salivary gland pain, Aphthous ulcer, Visual acuity reduced, Fatigue, |
||||
DATOPOTAMAB DERUXTECAN, OLANZAPINE, |
||||
| 207 | 26901985 |
EU |
72 | 1 |
Adenocarcinoma, Disease progression, |
||||
OLAPARIB, DOCETAXEL, DOCETAXEL ANHYDROUS, ENZALUTAMIDE, CABAZITAXEL, |
||||
| 208 | 26902323 |
EU |
77 | |
Disease progression, |
||||
ZANUBRUTINIB, ZANUBRUTINIB, RITUXIMAB, RITUXIMAB, VENETOCLAX, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN, VINCRISTINE SULFATE, PREDNISONE, BREXUCABTAGENE AUTOLEUCEL, PIRTOBRUTINIB, |
||||
| 209 | 26902473 |
2 | ||
Disease progression, Drug intolerance, |
||||
DATOPOTAMAB DERUXTECAN, |
||||
| 210 | 26908383 |
1 | ||
Disease progression, |
||||
BELZUTIFAN, |
||||
| 211 | 26891888 |
EU |
78 | 1 |
Disease progression, |
||||
ENZALUTAMIDE, DOCETAXEL, DOCETAXEL ANHYDROUS, DOCETAXEL, DOCETAXEL ANHYDROUS, CABAZITAXEL, |
||||
| 212 | 26892017 |
BR |
78 | |
Disease progression, |
||||
OSIMERTINIB, |
||||
| 213 | 26892021 |
6 | 2 | |
Disease progression, Off label use, |
||||
HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CREAM 1%, HYDROCORTISONE CREAM 1/2%, ANTI-PRURITIC, HYDROCORTISONE CONTINUOUS SPRAY, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, DIAZEPAM, DIAZEPAM ORAL, DIAZEPAM ORAL SOLUTION (CONCENTRATE), MANNITOL, EPINEPHRINE, ADRENALINUM, |
||||
| 214 | 26892121 |
EU |
76 | 1 |
Death, Idiopathic pulmonary fibrosis, Disease progression, Cough, Gastrointestinal disorder, Respiratory symptom, Weight decreased, |
||||
NINTEDANIB, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, PIRFENIDONE, MORPHINE, |
||||
| 215 | 26892176 |
MX |
49 | 1 |
Hypoventilation, Cachexia, Fatigue, Hepatic neoplasm, Dry mouth, Drug ineffective, Hypophagia, Oedema, Asthenia, Somatic pain, Visceral pain, Disease progression, |
||||
CAPECITABINE, BEVACIZUMAB, OXALIPLATIN, |
||||
| 216 | 26892382 |
EU |
61 | |
Death, Disease progression, |
||||
RITUXIMAB, GLOFITAMAB, POLATUZUMAB VEDOTIN, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DOXORUBICIN, PREDNISONE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, BENDAMUSTINE HCL, |
||||
| 217 | 26892534 |
EU |
80 | |
Disease progression, Therapy partial responder, |
||||
DENOSUMAB, EXEMESTANE, PALBOCICLIB, |
||||
| 218 | 26893085 |
EU |
1 | |
Death, Disease progression, |
||||
CILTACABTAGENE AUTOLEUCEL, |
||||
| 219 | 26893482 |
EU |
70 | 2 |
Bronchopulmonary aspergillosis, Disease progression, Creatinine renal clearance decreased, Therapy non-responder, |
||||
ISAVUCONAZONIUM SULFATE, ANIDULAFUNGIN, AMPHOTERICIN B, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, AZITHROMYCIN, AZITHROMYCIN MONOHYDRATE, AZITHROMYCIN DIHYDRATE, AZITHROMYCIN, AZITHROMYCIN MONOHYDRATE, AZITHROMYCIN DIHYDRATE, |
||||
| 220 | 26893485 |
UA |
1 | |
Disease progression, |
||||
LENALIDOMIDE, BORTEZOMIB, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, BENDAMUSTINE HCL, |
||||
| 221 | 26893496 |
US |
72 | 1 |
Disease progression, |
||||
DECITABINE, |
||||
| 222 | 26893526 |
RU |
44 | 2 |
Disease progression, |
||||
HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, |
||||
| 223 | 26893671 |
RU |
62 | |
Disease progression, |
||||
OBINUTUZUMAB, BENDAMUSTINE HCL, |
||||
| 224 | 26893801 |
EU |
64 | 1 |
Disease progression, |
||||
ZOLEDRONIC ACID, CINACALCET, |
||||
| 225 | 26894263 |
EU |
30 | 1 |
Product ineffective for unapproved use, Disease progression, Transaminases increased, Product prescribing issue, |
||||
METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, DOXORUBICIN, DOXORUBICIN, DOXORUBICIN, DOXORUBICIN, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, ETOPOSIDE, ETOPOSIDE, ETOPOSIDE, ETOPOSIDE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, CYCLOSPORINE, CYCLOSPORINE, CYCLOSPORINE, CYCLOSPORINE, |
||||
| 226 | 26894269 |
EU |
1 | |
Drug ineffective, Disease progression, Drug eruption, |
||||
LENALIDOMIDE, LENALIDOMIDE, LENALIDOMIDE, LENALIDOMIDE, BORTEZOMIB, BORTEZOMIB, BORTEZOMIB, BORTEZOMIB, BORTEZOMIB, BORTEZOMIB, BORTEZOMIB, BORTEZOMIB, MELPHALAN HYDROCHLORIDE, MELPHALAN, MELPHALAN HYDROCHLORIDE, MELPHALAN, MELPHALAN HYDROCHLORIDE, MELPHALAN, MELPHALAN HYDROCHLORIDE, MELPHALAN, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, |
||||
| 227 | 26894272 |
EU |
80 | 2 |
Chronic kidney disease, Pulmonary sepsis, Diffuse large B-cell lymphoma, Disease progression, |
||||
LENALIDOMIDE, LENALIDOMIDE, LENALIDOMIDE, |
||||
| 228 | 26894282 |
US |
40 | |
Disease progression, Off label use, |
||||
TOVORAFENIB, |
||||
| 229 | 26894416 |
GB |
9 | 1 |
Respiratory failure, Disease progression, |
||||
| 230 | 26894684 |
EU |
14 | 1 |
Disease progression, |
||||
ISOTRETINOIN, MINOCYCLINE, MESALAMINE, SALICYLIC ACID, MEDICATED CORN REMOVERS, LIQUID WART REMOVER, ULTRA THIN CORN REMOVERS, EXTRA THICK CALLUS REMOVERS, MEDICATED WART REMOVERS, CORN AND CALLUS REMOVER KIT, WART REMOVERS, WART REMOVER LIQUID, MEDICATED CALLUS REMOVERS, WART REMOVER GEL, MEDICATED PLANTAR WART REMOVER, MEDICATED CALLUS REMOVERS EXTRA THICK, MEDICATED CORN REMOVER, WART REMOVER, CLEAR MEDICATED CORN REMOVERS, CORN REMOVERS, BOSYE BENEFITING HAIR LOTION, LIQUID CORN AND CALLUS REMOVER, WART REMOVER MEDICATED DISCS, WART REMOVER GEL TUBE, SALICYLIC ACID 12%, CALLUS REMOVERS, CORN AND CALLUS REMOVER, GEL CORN REMOVER, ASTRINGENT, AZATHIOPRINE, INFLIXIMAB, |
||||
| 231 | 26895834 |
JP |
||
Disease progression, Dysphagia, |
||||
NINTEDANIB, |
||||
| 232 | 26895940 |
PK |
66 | 1 |
Disease progression, |
||||
BEVACIZUMAB, ATEZOLIZUMAB, |
||||
| 233 | 26896033 |
CN |
||
Disease progression, |
||||
DEGARELIX, |
||||
| 234 | 26896188 |
BR |
45 | |
Disease progression, |
||||
OSIMERTINIB, |
||||
| 235 | 26896277 |
|||
Disease progression, |
||||
OSIMERTINIB, PEMETREXED, PEMETREXED DISODIUM, |
||||
| 236 | 26896337 |
2 | ||
Disease progression, Therapy change, Blood glucose increased, |
||||
RIBOCICLIB, CAPIVASERTIB, |
||||
| 237 | 26896458 |
77 | 1 | |
Death, Metastases to liver, Disseminated intravascular coagulation, Disease progression, Platelet count decreased, |
||||
RADIUM RA 223 DICHLORIDE, DENOSUMAB, DEGARELIX, |
||||
| 238 | 26896698 |
CA |
2 | |
Adverse event, Clostridium difficile infection, Diarrhoea, Syncope, Blood test abnormal, Gait disturbance, Product dose omission issue, Disease progression, Vomiting, Asthenia, Fatigue, Abdominal discomfort, Weight decreased, Nausea, Dizziness, Fall, Asthenia, |
||||
NINTEDANIB, |
||||
| 239 | 26896713 |
AU |
68 | |
Disease progression, |
||||
BREXUCABTAGENE AUTOLEUCEL, |
||||
| 240 | 26897468 |
JP |
||
Disease progression, Infection, |
||||
MOMELOTINIB, |
||||
| 241 | 26906416 |
1 | ||
Drug ineffective, Disease progression, Therapy cessation, |
||||
TEMOZOLOMIDE, TEMOZOLOMIDE, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, AMLODIPINE, CHLORTHALIDONE, ESCITALOPRAM, ESCITALOPRAM OXALATE, ESCITSLOPRAM, |
||||
| 242 | 26886717 |
RU |
||
Disease progression, Pyrexia, Cytokine release syndrome, Hypogammaglobulinaemia, |
||||
GLOFITAMAB, |
||||
| 243 | 26886734 |
EU |
86 | 1 |
Disease progression, |
||||
NERANDOMILAST, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, |
||||
| 244 | 26887120 |
EU |
82 | 1 |
Disease progression, |
||||
ENZALUTAMIDE, DOCETAXEL, DOCETAXEL ANHYDROUS, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, |
||||
| 245 | 26887288 |
US |
20 | 1 |
Disease progression, |
||||
OMAVELOXOLONE, |
||||
| 246 | 26887694 |
EU |
77 | |
Disease progression, Hypertrophic cardiomyopathy, Hyperuricaemia, |
||||
RITUXIMAB, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, |
||||
| 247 | 26887695 |
CA |
61 | |
Disease progression, Drug ineffective, Suspected off label use, |
||||
USTEKINUMAB, USTEKINUMAB, ROSUVASTATIN, PANTOPRAZOLE, |
||||
| 248 | 26888208 |
SG |
||
Disease progression, |
||||
GLOFITAMAB, |
||||
| 249 | 26888322 |
JP |
51 | 1 |
Disease progression, Anaphylactic reaction, Drug resistance, |
||||
AMPHOTERICIN B, VORICONAZOLE, VORICONAZOLE INJECTION, METHYLPREDNISOLONE, METHYLPREDNISOLONE, |
||||
| 250 | 26888350 |
EU |
80 | 2 |
Chronic kidney disease, Pulmonary sepsis, Diffuse large B-cell lymphoma, Disease progression, |
||||
LENALIDOMIDE, LENALIDOMIDE, LENALIDOMIDE, |
||||
| 251 | 26888367 |
JP |
6 | 1 |
Disease progression, |
||||
ZANUBRUTINIB, |
||||
| 252 | 26888440 |
AU |
2 | |
Disease progression, |
||||
OBINUTUZUMAB, RITUXIMAB, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DOXORUBICIN, LENALIDOMIDE, |
||||
| 253 | 26888545 |
US |
1 | |
Hypoaesthesia, Headache, Fatigue, Disease progression, Treatment failure, |
||||
TERIFLUNOMIDE, |
||||
| 254 | 26888696 |
EU |
79 | 2 |
Disease progression, |
||||
VENETOCLAX, VENETOCLAX, FUROSEMIDE, SPIRONOLACTONE, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, METOPROLOL TARTRATE, METOPROLOL, METOPROLOL TARTRATE INJECTION, ENTECAVIR, ENTECAVIR ANHYDROUS, |
||||
| 255 | 26888705 |
EU |
72 | 1 |
Disease progression, Muscular weakness, Thrombocytopenia, Malaise, Cachexia, Anaemia, |
||||
VENETOCLAX, CLOPIDOGREL, CLOPIDOGREL BISULFATE, PIPERACILLIN SODIUM,TAZOBACTAM SODIUM, LINAGLIPTIN, RABEPRAZOLE, CARVEDILOL, VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN, CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFOLXACIN, CIPROFLOXACIN TABLETS, |
||||
| 256 | 26888762 |
US |
77 | 1 |
Disease progression, Neoplasm malignant, |
||||
LENALIDOMIDE, |
||||
| 257 | 26889446 |
PK |
74 | 2 |
Ovarian cancer recurrent, Disease progression, |
||||
BEVACIZUMAB, |
||||
| 258 | 26889672 |
1 | ||
Disease progression, |
||||
PIRTOBRUTINIB, |
||||
| 259 | 26890453 |
CN |
47 | 1 |
Disease progression, |
||||
LINEZOLID, ISAVUCONAZONIUM SULFATE, AMPHOTERICIN B, |
||||
| 260 | 26890545 |
8 | 2 | |
Disease progression, Nausea, |
||||
DATOPOTAMAB DERUXTECAN, |
||||
| 261 | 26890795 |
US |
28 | 2 |
Disease progression, |
||||
OMAVELOXOLONE, |
||||
| 262 | 26891415 |
AU |
59 | 1 |
Facial paresis, Hypercapnia, Hypotension, Muscular weakness, Condition aggravated, Disease progression, Off label use, |
||||
OXYCODONE HYDROCHLORIDE, OXYCODONE, CABOZANTINIB, CLONAZEPAM, LORAZEPAM, METOPROLOL TARTRATE, METOROPROLOL TARTRATE, METOPROLOL, APIXABAN, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE, MIRTAZAPINE, MIRTAZAPINE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, |
||||
| 263 | 26894419 |
76 | 1 | |
Disease progression, Idiopathic pulmonary fibrosis, |
||||
PIRFENIDONE, |
||||
| 264 | 26882253 |
US |
73 | 2 |
Mycobacterium avium complex infection, Pneumonia, Disease progression, Adverse reaction, |
||||
AMIKACIN, AMIKACIN SULFATE, AZITHROMYCIN, AZITHROMYCIN MONOHYDRATE, AZITHROMYCIN DIHYDRATE, RIFAMPIN, |
||||
| 265 | 26882624 |
EU |
68 | 1 |
Angioedema, Disease progression, Transaminases increased, Diarrhoea, |
||||
PIRFENIDONE, NINTEDANIB, LOSARTAN, TORSEMIDE, SIMVASTATIN, ESOMEPRAZOLE, ESOMEPRAZOLE MAGNESIUM, CALCIUM, |
||||
| 266 | 26882785 |
JP |
3 | 1 |
Disease progression, Obliterative bronchiolitis, |
||||
TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, AZACITIDINE, AZACITIDINE FOR, AZACITIDINE, AZACITIDINE FOR, AZACITIDINE, AZACITIDINE FOR, CYTARABINE, CYTARABINE, CYTARABINE, RUXOLITINIB, RUXOLITINIB, |
||||
| 267 | 26882909 |
JP |
66 | 1 |
Cytokine release syndrome, Disease progression, |
||||
| 268 | 26883242 |
IN |
||
Disease progression, |
||||
ATEZOLIZUMAB, |
||||
| 269 | 26883256 |
CN |
25 | 2 |
Drug ineffective, Disease progression, |
||||
CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, LORATADINE, LORATADINE ORAL, |
||||
| 270 | 26883565 |
US |
78 | 1 |
Disease progression, |
||||
| 271 | 26883575 |
CH |
||
Disease progression, |
||||
GLOFITAMAB, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, OXALIPLATIN, |
||||
| 272 | 26883626 |
US |
64 | 2 |
Disease progression, Acute hepatic failure, |
||||
DEXAMETHASONE, DEXAMETHASONE 1.5 MG, ETOPOSIDE, |
||||
| 273 | 26883627 |
JP |
62 | 1 |
Disease progression, |
||||
CAPECITABINE, OXALIPLATIN, BEVACIZUMAB, |
||||
| 274 | 26883630 |
US |
10 | 1 |
Disease progression, |
||||
PREDNISONE, |
||||
| 275 | 26883756 |
BR |
58 | |
Disease progression, |
||||
OSIMERTINIB, |
||||
| 276 | 26883792 |
EU |
1 | |
Disease progression, Prostatic specific antigen increased, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 277 | 26883914 |
US |
2 | |
Temperature intolerance, Disease progression, Flushing, Dizziness, |
||||
TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, VALACYCLOVIR, VALACYCLOVIR HYDROCHLORIDE, METFORMIN HYDROCHLORIDE, METFORMIN, METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS, METFORMIN HYDROCHLORIDE TABLET, METFORMIN HYDROCHLORIDE TABLETS, ZOLPIDEM TARTRATE, VILAZODONE HYDROCHLORIDE, ACETAMINOPHEN, MACITENTAN, ERGOCALCIFEROL, TADALAFIL, LAMOTRIGINE, ALPRAZOLAM, CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE, ATOMOXETINE HYDROCHLORIDE, BUMETANIDE, DIPHENHYDRAMINE HYDROCHLORIDE, OXYGEN, 0XYGEN, OXYCODONE HYDROCHLORIDE, OXYCODONE, CETIRIZINE HCL, CETIRIZINE, BENZONATATE, |
||||
| 278 | 26883930 |
CH |
69 | |
Disease progression, Pulmonary embolism, Thrombosis, Blood lactate dehydrogenase increased, COVID-19, Malignant pleural effusion, Superinfection bacterial, Cytopenia, Thrombocytopenia, Electrolyte imbalance, Type 2 diabetes mellitus, Product use issue, Product use in unapproved indication, |
||||
DUVELISIB, DUVELISIB, BELINOSTAT, BELINOSTAT, CYTARABINE, ETOPOSIDE, |
||||
| 279 | 26884428 |
US |
2 | |
Drug ineffective, Disease progression, Product prescribing issue, |
||||
LENALIDOMIDE, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, POMALIDOMIDE, DARATUMUMAB, IXAZOMIB, |
||||
| 280 | 26884440 |
US |
73 | 2 |
Drug ineffective, Disease progression, |
||||
PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), DOXORUBICIN, DOXORUBICIN, CAPECITABINE, CAPECITABINE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, LETROZOLE, LETROZOLE TABLETS, LETROZOLE, LETROZOLE TABLETS, IVERMECTIN, IVERMECTIN, IVERMECTIN, IVERMECTIN, NOREPINEPHRINE (BITARTRATE), NOREPINEPHRINE, NOREPINEPHRINE BITARTRATE, LEVETIRACETAM, LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM ORAL, LEVETIRACETAM INJECTION, LEVETIRACETAM, LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM ORAL, LEVETIRACETAM INJECTION, |
||||
| 281 | 26884448 |
EU |
30 | 1 |
Disease progression, |
||||
PREDNISONE, DOXORUBICIN, ETOPOSIDE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, |
||||
| 282 | 26884466 |
IN |
42 | 2 |
Disease progression, Colorectal cancer metastatic, |
||||
CAPECITABINE, BEVACIZUMAB, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, OXALIPLATIN, ERGOCALCIFEROL, PANTOPRAZOLE, URSODIOL, URSOSIOL, TELMISARTAN, FENTANYL, PEGFILGRASTIM, |
||||
| 283 | 26884591 |
RS |
66 | 1 |
Hydronephrosis, Oliguria, Vomiting, Nausea, Disease progression, |
||||
AVELUMAB, |
||||
| 284 | 26884807 |
2 | ||
Death, Disease progression, Weight fluctuation, Laboratory test abnormal, Weight decreased, Incorrect product administration duration, Product dose omission issue, Off label use, |
||||
FAM-TRASTUZUMAB DERUXTECAN-NXKI, FAM-TRASTUZUMAB DERUXTECAN-NXKI, FAM-TRASTUZUMAB DERUXTECAN-NXKI, FAM-TRASTUZUMAB DERUXTECAN-NXKI, FAM-TRASTUZUMAB DERUXTECAN-NXKI, FAM-TRASTUZUMAB DERUXTECAN-NXKI, FAM-TRASTUZUMAB DERUXTECAN-NXKI, FAM-TRASTUZUMAB DERUXTECAN-NXKI, FAM-TRASTUZUMAB DERUXTECAN-NXKI, |
||||
| 285 | 26884818 |
35 | 2 | |
Disease progression, Off label use, |
||||
FAM-TRASTUZUMAB DERUXTECAN-NXKI, |
||||
| 286 | 26884820 |
76 | 1 | |
Myelosuppression, Disease progression, Pneumonitis, |
||||
FAM-TRASTUZUMAB DERUXTECAN-NXKI, |
||||
| 287 | 26884893 |
RU |
39 | 1 |
Disease progression, Off label use, |
||||
OBINUTUZUMAB, CISPLATIN, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, ETOPOSIDE, |
||||
| 288 | 26884895 |
MX |
57 | |
Disease progression, Metastasis, |
||||
NERATINIB, CAPECITABINE, |
||||
| 289 | 26885095 |
7 | 1 | |
Platelet count decreased, Disease progression, |
||||
FAM-TRASTUZUMAB DERUXTECAN-NXKI, FAM-TRASTUZUMAB DERUXTECAN-NXKI, |
||||
| 290 | 26885097 |
2 | ||
Disease progression, |
||||
DATOPOTAMAB DERUXTECAN, |
||||
| 291 | 26885099 |
73 | 2 | |
Disease progression, Eye pain, Ocular hyperaemia, |
||||
DATOPOTAMAB DERUXTECAN, |
||||
| 292 | 26885369 |
EU |
1 | |
Haematotoxicity, Disease progression, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 293 | 26885551 |
45 | 2 | |
Disease progression, Infusion related reaction, Pneumonitis, |
||||
DATOPOTAMAB DERUXTECAN, DATOPOTAMAB DERUXTECAN, DATOPOTAMAB DERUXTECAN, |
||||
| 294 | 26885553 |
7 | 2 | |
Disease progression, |
||||
FAM-TRASTUZUMAB DERUXTECAN-NXKI, |
||||
| 295 | 26885555 |
76 | ||
Disease progression, |
||||
FAM-TRASTUZUMAB DERUXTECAN-NXKI, SACITUZUMAB GOVITECAN, |
||||
| 296 | 26886129 |
EU |
48 | 2 |
Drug ineffective, Disease progression, Palmar-plantar erythrodysaesthesia syndrome, Product prescribing issue, |
||||
METHOTREXATE, METHOTREXATE SODIUM, CAPECITABINE, CISPLATIN, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, PEMBROLIZUMAB, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, |
||||
| 297 | 26886419 |
BR |
1 | |
Disease progression, |
||||
TISLELIZUMAB-JSGR, TISLELIZUMAB-JSGR, |
||||
| 298 | 26876649 |
CA |
||
Disease progression, |
||||
OSIMERTINIB, |
||||
| 299 | 26876801 |
JP |
50 | 2 |
Disease progression, Skin disorder, |
||||
TISLELIZUMAB-JSGR, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, CISPLATIN, |
||||
| 300 | 26877188 |
PK |
41 | 2 |
Disease progression, |
||||
TRASTUZUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-07-30